What is prior authorization in health insurance, and why do many physicians oppose it?
The Arguments
WHAT THE INDUSTRY ARGUES
Insurers and plan administrators argue that prior authorization serves as a necessary cost-control and quality-assurance tool. By requiring advance approval before covering certain drugs, procedures, or services, insurers say they can verify that a treatment is medically appropriate, prevent unnecessary or duplicative care, and steer patients toward evidence-based options. As illustrated in the Counterforcehealth.org guide, specialty drugs like Ibrance (palbociclib) — classified as Tier 4/5 medications — require prior authorization so the insurer can confirm pathology results and clinical criteria before approving expensive therapy, which supporters say protects both patients and the broader insurance pool from wasteful spending.
WHAT CRITICS ARGUE
Many physicians argue that prior authorization creates burdensome administrative delays that can harm patients. Doctors report spending significant staff time compiling documentation, submitting forms, and appealing denials — time that could be spent on direct patient care. Critics point to situations like those described in New York Post coverage, where promising treatments such as GLP-1 drugs for addiction remain difficult to access because insurance coverage hurdles, including prior authorization requirements, slow or block patient access to therapies their doctors have already deemed appropriate. Physicians contend the process effectively allows insurance companies to override clinical judgment, sometimes forcing patients to wait days or weeks for treatment approval.
The Data
WHAT THE DATA SHOWS
The available source material does not include government data such as CMS statistics on prior authorization volume or denial rates. However, the Counterforcehealth.org guide demonstrates the complexity of the process for a single specialty drug, requiring oncologist-submitted documentation including pathology results for insurer review. The New York Post article highlights how insurance coverage barriers can delay access to clinically promising medications.
The Bottom Line
BOTTOM LINE
Prior authorization is an insurer requirement for pre-approval of certain treatments, defended as a cost-control measure by insurers and criticized by physicians as an administrative burden that can delay patient care.